Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Back

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Recruiting

Open to: ALL

Age: 18.0 - N/A

Taunton Birmingham Birmingham Cringleford Glasgow Plymouth Leeds

Medical Conditions

Multiple Myeloma
Neoplasms, Plasma Cell

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jan 2023 Feb 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : MeziKd (Mezigdomide + Carfilzomib + Dexamethasone);

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Kd (Carfilzomib + Dexamethasone);MeziKd (Mezigdomide + Carfilzomib + Dexamethasone);

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Kd (Carfilzomib + Dexamethasone);MeziKd (Mezigdomide + Carfilzomib + Dexamethasone);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Musgrove Park Hospital
    Taunton
    TA1 5DA
  • Heartlands Hospital
    Birmingham
    B9 5SS
  • Local Institution - 0039
    Birmingham
    B15 2TH
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
    Cringleford
    England
    NR4 7UY
  • The Beatson West of Scotland Cancer Centre
    Glasgow
    Glasgow City
    G12 0YN
  • Derriford Hospital
    Plymouth
    Devon
    Pl6 8DH
  • St James's University Hospital
    Leeds
    LS9 7TF

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.



The study is sponsored by Bristol-Myers Squibb



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05552976
Last updated 22 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top